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Peroxisomes are essential organelles in higher eukaryotes as they play a major role in numerous
metabolic pathways and redox homeostasis. Some peroxisomal abnormalities, which are often not
compatible with life or normal development, were identiﬁed in severe demyelinating and neurode-
generative brain diseases. The metabolic roles of peroxisomes, especially in the brain, are described and
human brain peroxisomal disorders resulting from a peroxisome biogenesis or a single peroxisomal
enzyme defect are listed. The brain abnormalities encountered in these disorders (demyelination,
oxidative stress, inﬂammation, cell death, neuronal migration, differentiation) are described and their
pathogenesis are discussed. Finally, the contribution of peroxisomal dysfunctions to the alterations of
brain functions during aging and to the development of Alzheimer’s disease is considered.
 2013 Elsevier Masson SAS. All rights reserved.Peroxisomes are DNA free organelles present in nearly all
eukaryotic cells (with the exception of erythrocytes) including
unicellular eukaryotes and higher plant cells [1]. They are
morphologically characterized by a single limiting membrane and
a ﬁnely granular matrix with a range in size from 0.1 to 1 mm in
diameters (Fig. 1). However, peroxisome shape, size, and cellular
content show considerable variations in response to ﬁssion,
fusion, and proliferation mechanisms. Among the different or-
gans, peroxisomes are numerous in liver (hepatocytes) and
peroxisomal proteins expression has been detected in different
areas of the brain (especially cerebellum, hippocampus) and in all
neural cell types with a preponderance for glial cells (oligoden-
drocytes, astrocytes) [2]. In the cytoplasm, peroxisomes are
highly dynamic organelles with marked plasticity that have been, acyl-CoA oxidase; AD, Alz-
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son SAS. All rights reserved.shown to move in a motor protein-dependent manner along
microtubules in mammals [3] or actin ﬁlaments in plants and
fungi [4]. As peroxisomes lack DNA, most of the peroxisomal
membrane and matrix proteins are synthesized on free poly-
ribosomes in the cytoplasm and are then transported post-
translationally to the organelle. So, speciﬁc proteins import
pathways are required. They include two classes of matrix tar-
geting signals for peroxisomal proteins [PTS1 (Peroxisomal Tar-
geting Signal 1) and PTS2] which are recognized by cytosolic
receptors [PEX5 (peroxin 5) and PEX7, respectively] escorting
their cargo proteins to, or possibly across, the peroxisome
membrane.
The crucial roles of peroxisomes in human health became
obvious when some peroxisomal abnormalities, which are often
not compatible with life or normal development, were identiﬁed in
severe neurodegenerative and demyelinating brain diseases. This
review describes the metabolic role of peroxisomes with a special
focus on the brain and lists the human brain peroxisomal disorders
resulting from a peroxisome biogenesis defect or from a single
peroxisomal enzyme defect. We focused on the abnormalities of
myelination, oxidative stress, inﬂammation, cell death and
neuronal migration problems observed in brain peroxisomal dis-
orders and discussed the causes of these abnormalities. Finally, the
potential role of peroxisomes in brain degeneration is considered
with the involvement of peroxisomes in cell aging and in the
development of Alzheimer’s disease.
Fig. 1. Identiﬁcation of peroxisomes in neural cells. Peroxisomes can be identiﬁed in brain cells by various techniques: transmission electron microscopy (A, B), conventional and
confocal ﬂuorescence microscopy by using antibodies recognizing speciﬁc peroxisomal proteins as ABCD3 and catalase (C, D), and by ﬂow cytometry (insets: C, D) [55]. Dark arrows
point towards mitochondria and white arrows point towards peroxisomes.
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More than 50 enzymes participating in various metabolic
pathways, especially lipid and oxidative metabolic pathways, have
been identiﬁed [5]. The main peroxisomal functions concern lipid
metabolism with the b-oxidation of diverse compounds and the
a-oxidation of phytanic acid [6]. Peroxisomes are also crucial for
hydrogen peroxide detoxiﬁcation, via catalase activity and are also
involved in the degradation of purines, D-amino acids, polyamines,
eicosanoids and uric acid (in non-primates). In brain, one of the
main roles of peroxisomes is to degrade saturated very-long-chain
fatty acids (VLCFA) like C24:0 and C26:0 and to participate in the
equilibrium of these compounds particularly enriched in the
myelin. Peroxisomal b-oxidation of VLCFA consists in 4 enzymatic
steps: dehydrogenation, hydration, dehydrogenation again, thio-
lytic cleavage releasing a shortened fatty acid and acetyl-CoA [6].
The released fatty acid undergoes subsequent rounds of b-oxida-
tion till the formation of octanoyl-CoA. Carnitine octanoyl-
transferase catalyzing the exchange of acyl groups between
carnitine and coenzyme A (CoA) contributes to connect peroxi-
somes with mitochondria, octanoyl-carnitine being transported to
the mitochondria to be fully degraded. Peroxisomal b-oxidation
also concerns monounsaturated (MUFA), polyunsaturated fatty
acids (PUFA) and their derivatives (eicosanoids and docosanoids),
2-methyl branched-chain fatty acids and dicarboxilic acids whoseexcesses can be as toxic as the accumulation of saturated VLCFA [6].
Degradation of eicosanoids is of particular importance given the
inﬂammatory pathways that depend on these molecules. Arach-
idonic (C20:4 n-6) and eicosapentaenoic (C20:5 n-3) acids, and
their derivatives (prostaglandins, leukotrienes, prostacyclins,
thromboxanes) are the known mediators of a broad range of in-
ﬂammatory reactions [7].
Peroxisomal b-oxidation may not be considered as a simple
catabolic pathway since the last step of the synthesis of docosa-
hexaenoic acid (DHA, C22:6 n-3) involves one turn of b-oxidation
from C24:6 n-3 [8]. DHA is the best represented PUFA in brain and
nervous tissues. In addition to its structural role in membrane
lipids, DHA has been shown to act at different levels in brain for
neurotransmission, synaptic plasticity, gene expression, calcium
concentration homeostasis [7,9]. Its enzymatic conversion to
resolvins, neuroprotectins and maresins provides very active anti-
inﬂammatory molecules that can inhibit the generation of prosta-
glandins, leukotrienes, and thromboxanes [10,11]. The brain con-
centration of DHA depends on both dietary content in n-3 PUFA and
liver synthesis [12]. Another important function of peroxisomes in
the brain concerns the synthesis of plasmalogens since the ﬁrst 2
steps of this anabolic pathway take place in peroxisomes [13].
After the acylation of dihydroxyacetone phosphate, which forms a
1-acyl-DHAP, the acyl group is replaced by a fatty alcohol synthe-
tized within peroxisomes from acyl-CoA [14]. The 1-alkyl-DHAP is
D. Trompier et al. / Biochimie 98 (2014) 102e110104then reduced to yield a 1-alkyl-phosphoglycerol which is further
processed in the endoplasmic reticulum. The major predicted
roles of plasmalogens are to contribute to membrane ﬂuidity, to
buffer oxidative stress and to serve as reservoirs for second mes-
sengers [15].
Beyond their role in lipid metabolism, peroxisomal functions are
involved in the control of oxidative stress homeostasis [5]. Perox-
isomal enzymes such as acyl-CoA oxidases (ACOX) or inducible
nitric oxide synthase (iNOS) [16] are known to generate oxidative
stress with reactive oxygen species (ROS) and reactive nitrogen
species (RNS). ROS molecules, especially superoxide anions (O2)
and hydrogenperoxide (H2O2), and RNSmolecules with nitric oxide
(NO), are produced in part in peroxisomes [17]. In the same time,
peroxisomes possess enzymatic components which counteract the
oxidative and nitrosative stress. These enzymes include catalase,
superoxide dismutase 1, or glutathione S-transferase [17].
2. Human brain peroxisome disorders
Peroxisomes contribute to central metabolic pathways in the
brain and their functional importance in human health is high-
lighted by peroxisomal disorders. Currently, these disorders are
classiﬁed into two groups: i) peroxisome biogenesis disorders
(PBDs) and ii) single peroxisomal enzyme deﬁciencies (Table 1).
2.1. Peroxisome biogenesis disorders
The PBDs result from a failure in organelle formation leading to
multiplemetabolic abnormalities. The PBDs can be divided into two
subtypes; i) the Zellweger syndrome spectrum (ZSS) disorders and
ii) the rhizomelic chondrodysplasia punctata (RCDP) type 1.
The ZSS is a group of inherited diseases which consists of at least
three different but overlapping clinical phenotypes with variable
severity of neurologic symptoms [18]. The Zellweger syndrome (ZS)
is the most severe form, the neonatal adrenoleukodystrophy
(NALD) is intermediate and the infantile Refsum disease (IRD) is the
less severe phenotype. PBDs are autosomal recessive disorders all
caused by a defect in PEX genes which encode for peroxins, proteins
necessary for peroxisome biogenesis and involved in the import
process of peroxisomal integral membrane andmatrix proteins. It is
not possible to predict the defective PEX gene from the biochemical
or clinical phenotype. However, the type of mutation of the
defective PEX gene correlates with the clinical severity and with the
impact on peroxisome function and assembly. Biochemical abnor-
malities are less severe in patients with milder form of PBDs whose
skin ﬁbroblasts contain residual peroxisome activity. Cells from
patients with severe ZS are devoid of peroxisomes.
RCDP type 1 is clinically clearly distinct from the ZSS disorders.
Patients with RCDP type 1 have mutations in PEX7 gene which
encodes a cytosolic receptor that directs PTS2 peroxisomal matrix
enzymes to the peroxisomes. Three PTS2 enzymes are transported
by PEX7: the ACAA1 thiolase of the b-oxidation pathway, the
phytanoyl-CoA hydroxylase of the a-oxidation pathway, and the
alkyl-DHAP synthase involved in the synthesis of plasmalogens.
The function of ACCA1 can be taken over by a second thiolase
(SCPx) transported to the peroxisomes by PEX5, explaining why
plasma VLCFA levels are normal in RCDP patients. However,
defective targeting of the alkyl-DHAP synthase and the phytanoyl-
CoA hydroxylase leads to plasmalogen deﬁciency and also to phy-
tanic acid accumulation [19].
2.2. Single peroxisomal enzyme deﬁciencies
The second category of peroxisomal disorders includes disor-
ders which result from the deﬁciency of a single peroxisomalenzyme involved in b-oxidation, a-oxidation or ether lipid
synthesis.
Four main deﬁned disorders of peroxisomal b-oxidation have
been identiﬁed; i) X-linked adrenoleukodystrophy (X-ALD), ii) acyl-
CoA oxidase 1 deﬁciency (or PNALD; pseudo-neonatal adrenoleu-
kodystrophy), iii) D-bifunctional protein deﬁciency (DBPD) and iv)
a-methyl-acyl-CoA-racemase (AMACR) deﬁciency. X-ALD is the
most common peroxisomal disorder with impaired b-oxidation of
saturated VLCFA resulting in the accumulation of VLCFA in plasma
and tissues, which is a reliable diagnostic marker of the disease. In
X-ALD brain, increased VLCFA levels are found especially in the
cholesterol ester fraction but also in cerebrosides, phosphatidyl-
choline, sphingomyelin and sulfatides [20]. This complex neuro-
degenerative disorder is characterized by a huge clinical variability
both in the age of onset and in symptoms. The responsible gene for
X-ALD is the ABCD1 gene which encodes for a peroxisomal ATP-
Binding Cassette (ABC) transporter involved in the transport of
VLCFA-CoA into the peroxisomes for their b-oxidation [21,22]. The
clinical presentation of PNALD and DBPD resembles that of the
disorders of peroxisome biogenesis although there are defects in
only one single enzymatic process. ACOX1 catalyzes the a, b-
dehydrogenation of a range of acyl-CoA esters among which satu-
rated VLCFA, resulting in elevated VLCFA levels in plasma of
patients although peroxisomes were present and even of enlarged
sizes. The D-bifunctional protein deﬁciency causes abnormal
oxidation of VLCFA, pristanic acid and di- and trihydrox-
ycholestanoic acids (DHCA, THCA) resulting in their accumulation
in plasma of patients. The AMACR deﬁciency is a rare autosomal
recessive disorder that was reported in ten adults and four infants
worldwide. The enzyme catalyzes the interconversion of (2R)- and
(2S)-stereoisomers of a-methyl branched-chain fatty acids (such as
pristanic acid), DHCA and THCA, which explains the accumulation
of pristanic acid and bile-acid intermediates in patients.
The absence of the ﬁrst enzyme involved in the a-oxidation
pathway, the phytanoyl-CoA hydroxylase, is responsible for Refsum
disease (RD). All patients accumulate phytanic acid in blood and
tissues. Rhizomelic chondrodysplasia punctata (RCDP) of type 2
and of type 3 are lethal disorders, respectively associated with
mutation in the GNPAT and AGPS genes that encode for the two
enzymes (DHAP acyltransferase and alkyl DHAP synthase) cata-
lyzing the ﬁrst steps of ether lipid biosynthesis in peroxisomes. The
clinical phenotypes are indistinguishable from that of patients with
RCDP of type 1 and these disorders are characterized by decreased
levels of plasmalogens.
3. Physiopathological consequences of peroxisomal
dysfunctions
3.1. Differentiation and neuronal migration abnormalities
Abnormalities in neuronal migration are classically seen in ZS,
NALD and DBPD patients [23]. The neuronal migration defects are
less prominent in NALD patients and often indistinguishable be-
tween ZS and DBPD patients. Only few cases among IRD and RCDP
patients have displayed cerebral neuronal migration problems [23].
ZS neuropathological features include impaired brain neuronal
migration leading to characteristic cytoarchitectonic abnormalities
in the cerebral cortex and in the cerebellum [24]. The malformation
of the cerebral cortex is most severe, encountered postnatally and
on fetuses, and results from an impaired migration of neuroblasts
to form the cerebral cortical plate. The cerebellum contains het-
erotopic Purkinje cells in the white matter or combinations of
abnormally arranged Purkinje cells and granule neurons. In addi-
tion, defects in neuronal differentiation, proliferation and survival
may also contribute to the malformations, as assessed by in vivo
Table 1
Human brain peroxisome deﬁciencies and their pathologies. A plus sign (þ) denotes presence; absence of sign means either there is no defect or that the defect has not been described (yet); aþ/ sign denotes that the symptom
may or may not be present. For biochemical features, the presence (þ) of increased and decreased levels of fatty acids/lipids are indicated.
Disease Peroxisome biogenesis disorders (PBD) Single peroxisomal enzyme deﬁciency
Zellweger syndrome spectrum RCDP
type 1
X-ALD PNALD DBP
deﬁciency
AMACR
deﬁciency
Refsum
disease
RCDP type 2 RCDP type 3
ZS NALD IRD
OMIM 215100 300100 264470 261515 614307 266500 222765 600121
Gene defect PEX 1,2,3,5,6,10,12,
13, 14,16,19 or 26
PEX 1,5,6,10,
12, 13, or 26
PEX 1,2,12
or 26
PEX 7 ABCD1 ACOX1 HSD17B4 AMACR PHYH GNPAT AGPS
Peroxisomes Absence (or “ghost”) Absence
(or “ghost”)
Absence
(or “ghost”)
þ þ þ (abnormal) þ (abnormal) þ þ þ þ
Clinical features
Hypotonia þ þ þ þ þ þ þ þ
Craniofacial dysmorphy þ þ þ þ þ þ þ þ
Skeletal defect þ þ þ þ þ þ þ þ þ
Growth retardation þ þ þ þ þ þ þ þ
Mental retardation þ þ þ þ þ/ þ þ þ/ þ þ
Spasticity þ þ þ þ þ þ þ þ þ þ
Seizure þ þ þ þ þ þ þ þ þ þ
Retinopathy/vision failure þ þ þ þ þ þ þ þ þ þ
Hearing failure þ þ þ þ þ þ þ þ
Anosmia þ
Neurological abnormalities
Brain development
Cortex malformation þ þ þ þ þ þ þ
Neuronal migration defect þ þ þ þ þ
Cerebellum malformation þ þ þ þ þ þ þ
Brain degeneration
Leukodystrophy þ þ þ þ þ þ þ/
Peripheral neuropathy þ þ þ þ/ þ þ þ þ
Biochemical features
Ether lipids (plasmalogens) Y þ þ þ þ þ þ þ
DHA Y þ þ þ þ þ
VLCFA [ þ þ þ þ þ þ
Branched-chain fatty acids [ þ þ þ þ þ þ þ þ
Bile-acid intermediates [ þ þ þ þ þ
Multiple impaired metabolic pathways Impaired b-oxidation Impaired
a-oxidation
Impaired ether lipid
biosynthesis
Survival (-year-old) <1 <10 Up to adulthood <10 <10 <5 <2 Normal
(under diet)
<10 <10
Approximative onset Newborna Newborna Newborna Newborna Childhood Newborna Newborna Adulthood Childhood Childhoodb Childhoodb
Abbreviations: ZS, Zellweger syndrome; NALD, neonatal adrenoleukodystrophy; IRD, infantile Refsum disease; RCDP, rhizomelic chondrodysplasia punctata; X-ALD, X-linked adrenoleukodystrophy; PNALD, pseudo-neonatal
adrenoleukodystrophy; DBP, D-bifunctional protein; AMACR, a-methyl-acyl-CoA-racemase; PEX, peroxin; ABCD1, ATP-Binding Cassette D1; ACOX, acyl-CoA oxidase; PHYH, phytanoyl-CoA hydroxylase; GNPAT, glycer-
onephosphate O-acyltransferase; AGPS, alkylglycerone-phosphate synthase; DHA, docosahexaenoic acid; VLCFA, very-long-chain fatty acid.
a In patients affected at birth, the onset is actually already during intrauterine development.
b RCDP type 2 and 3 can start as early as RCDP type 1.
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D. Trompier et al. / Biochimie 98 (2014) 102e110106studies in Pex2/ Zellweger mice [24]. The neuronal migration
abnormalities in DBPD are similar to those in ZS [25,26] and more
extensive than the abnormalities seen in NALD [27]. The precise
molecular mechanisms causing the neuronal migration and dif-
ferentiation defects remains obscure. The peroxisomal metabolism
in brain as well as in extraneuronal tissues inﬂuence the neuronal
migration process in Pex5 knock-out mice, a model for Zellweger
syndrome [28]. It seems unlikely that VLCFA accumulation, plas-
malogens depletion or DHA deﬁciency by themselves cause the
migration defect in peroxisomal disorders but they may rather
contribute to the defects.
3.2. Abnormal myelination
In humans, myelin production begins in the ﬁfth month of fetal
development in themotor roots of peripheral nervous system, and is
followed by myelination of the spinal cord and the brain. Although
normal myelination occurs mainly in the ﬁrst two years of life,
myelination continues for 20e30 years in the human cerebral
white matter. Myelin defects in brain peroxisomal disorders
include delayed myelination (with increasing content of myelin
over time), hypomyelination (with unchanged lack of myelin over
time), demyelination (degenerative loss of myelin) and dysmyeli-
nation (abnormally formed myelin). The clear distinction between
demyelination and abnormalmyelination is often rendered difﬁcult
before the ﬁrst two years of life when the two processes can occur
simultaneously [29].
Within the ZSS patients displaying amild and severe phenotype,
the disturbed function of peroxisomes is associated with brain
white matter abnormalities that can be demyelinative and/or dys-
myelinative [29]. All ZS patients have impaired myelination which
appears to be primarily a hypomyelination [30]. In NALD patients,
the progressive demyelination seen is diffuse and affects cerebral
and cerebellar hemispheres. In IRD patients, myelination is
abnormal, but there is no active demyelination. White matter may
be morphologically normal in ZSS patients surviving the ﬁrst year
[31]. The severity of myelin abnormalities is correlated with the
plasmalogen level in RCDP spectrum [32]. Indeed, no myelin ab-
normalities were seen in the patients with mild phenotype, and
delay in supratentorial white matter myelination was observed in
patients with the severe phenotype of both RCDP type 1 and 3. In
DBPD patients, magnetic resonance imaging studies may show
cerebral and cerebellar demyelination [33]. While demyelination in
the peripheral nervous system is documented in Refsum disease
patients, no myelin abnormalities have been evidence in the brain
[29]. X-ALD is a severe demyelinating disease characterized by a
progressive inﬂammatory demyelination in the brain, the pro-
gression being slower in the adolescent and adult forms compared
to the childhood form [34]. The most frequent pattern is the char-
acteristic symmetrical demyelination that occurs in the parieto-
occipital region.
The lack of myelination seen in PBD and RCDP type 2 and 3
patients may result from the depletion of plasmalogen levels
(major component of the normal myelin membrane). Abnormal
myelination may also be due to VLCFA accumulation in membrane
lipids. VLCFA are particularly enriched in myelin along with other
speciﬁc lipids [35,36]. VLCFA may contribute to myelin stability and
insulating properties. However, their excess is thought to physically
destabilize myelin sheath [23,37] and/or become toxic for nervous
cells in charge of myelin synthesis (oligodendrocytes) and brain
survey (microglia) [38,39]. VLCFA accumulation is more pro-
nounced in the center of X-ALD demyelination plaques, and is
therefore suspected to initiate the destabilization of the myelin
organization leading to cerebral demyelination [34]. Peroxisomes
are found in all neural cell types and their abundance decreasesfrom birth to adulthood. Alteration of peroxisomal functions in
oligodendrocytes appears to be the main pathogenic factor leading
to demyelination [34]. However, alteration of peroxisomal func-
tions in other brain cell types may contribute to aggravate the
pathological phenotype [40].
3.3. Inﬂammation
The part taken by peroxisomes in cytokinic inﬂammation was
established in the 90s, on brain lesions of patients with X-ALD
which revealed increased expression of pro-inﬂammatory cyto-
kines (IL-1, TNF-a) and ICAMs (Intercellular AdhesionMolecules) by
astrocytes and microglial cells [41e43]. To understand the role of
inﬂammation in X-ALD, the expression of inﬂammatory cytokines
in different regions of brain with the childhood form has been
investigated [44]. An increase of mRNA expression of different cy-
tokines (IL-1a, IL-2, IL-3, IL-6, TNF-a, GM-CSF), chemokines (CCL2,
-4, -7, -11, -21, -22, CXCL1, CX3CL1 and SDF-2) and iNOS was
observed in the active edge of demyelinating plaques of the brain
compared to normal looking area [44]. In addition, a spatial rela-
tionship between VLCFA accumulation and inﬂammation has been
evidenced [44]. Similar observations were obtained in mutant
mice where Pex5 is selectively inactivated in oligodendrocytes
with neuroinﬂammation characterized by an increase of pro-
inﬂammatory (TNF-a, IFN-g) and anti-inﬂammatory (IL-10) fac-
tors, and chemoattractants for lymphomononuclear cells (MIP-1a,
MCP-1, MCP-5 and IP-10) [45]. In the mouse model with neural
peroxisome dysfunction (Nestin-Pex5 knock-out mice) or in Pex1
mutant Drosophila, an induction of innate immunity was observed
in brain with up regulation of pathways related to immune re-
sponses: transendothelial migration, antigen processing and pre-
sentation (C1q, subcomponent of classical complement system, is
up-regulated in corpus callosum), cytokineecytokine receptor
interaction and toll-like receptor signaling pathways (TNF-a, TLR2
and Cxcl-1 up-regulated in corpus callosum before demyelination)
[46,47]. In mice with peroxisome deﬁciency in neural cells (Nestin-
Pex5/), the innate immune system is early activated (3 weeks
after birth), with strong and persistent inﬂammatory response [46].
Noteworthy, in X-ALD patients, a relationship between inﬂamma-
tion and oxidative stress has been suggested [48]. Indeed, some
redox sensors can be present in key regulators of inﬂammation, for
example NF-kB, which has redox-active cysteine residues, Nrf2. It
was proposed that high levels of ROS release by neural cells (glial
cells, neurons) may favor an inﬂammatory response [48].
Some studies also support that non cytokinic inﬂammation also
depends on peroxisomal activity since 5-lipoxygenase (5-LOX) and
cycloxygenase-2 (COX-2) are induced in Abcd1/Abcd2-silenced as-
trocytes [49]. Moreover, 5-LOX-derived leukotrienes were signiﬁ-
cantly elevated in all the areas of white matter in the brain of the
cerebral form of X-ALD. Unlike COX-2 expression, which was
moderately high only in the plaque area, expression of 5-LOX and
cytosolic phospholipase A2 was prominent in all the areas [49].
In the three hit hypothesis it is suggested that oxidative stress
triggers neuroinﬂammation contributing to cell death and demy-
elination [50].
4. Consequences of peroxisomal dysfunction at the cellular
level
4.1. Oxidative stress
The disturbance of redox homeostasis is thought to initiate and/
or amplify the progression of neurological diseases. Alterations of
peroxisomal functions contribute by themselves to this stress but
they have also consequences on the mitochondrial redox status
D. Trompier et al. / Biochimie 98 (2014) 102e110 107[51]. These consequences on mitochondria are apparently not
restricted to oxidative stress but would be also associated with
bioenergetic and metabolic failure [48]. Oxidative damages have
been documented in human X-ALD brain tissue with the childhood
form: increase mRNA expression of iNOS [44] and presence of lipid
peroxidation products (4-hydroxynonenal and malonedialdehyde)
[52]. Oxidative stress can also be observed in the case of deletion of
a single allele of the Pex11b gene inmice; this deletion inmice leads
to oxidative damage of the nucleic acid and to an increase of
manganese superoxide dismutase in cerebellum and neocortex
[53]. In Pex11b/ mice, a decrease in catalase is observed in
neocortex [53]. In a mouse model of Zellweger syndrome (Pex13
null mice), mitochondria-mediated oxidative stress in cultured
cerebellar neurons and in cerebellum sections was also reported
[54]. On murine oligodendrocyte 158N cells, by using siRNAs raised
against Abcd1 and Acox1, an increased overproduction of ROS and
RNS potentiated by VLCFA was also observed [38,55]. Gene
silencing leads to lipid peroxidation, enhanced accumulation of
lipids, and induction of cell death.
4.2. Cell death
In pathologies involving peroxisome dysfunction in brain, VLCFA
accumulation, oxidative stress and inﬂammation are associated
with cell death. The type of cell death is not well characterized:
necrosis or apoptosis are mentioned. Apoptosis (DNA ladder
pattern and terminal deoxynucleotidyl transferase staining) asso-
ciated with high level of ceramide and low level of GSH has been
described in X-ALD brain [56]. In the brain of X-ALD patients with
the cerebral phenotype, apoptosis mainly concerns oligodendro-
cytes with presence of activated-caspase-3 and fragmented DNA
[57]. Apoptosis is observed in brain areas with microglial activation
and can represent an early stage in lesion evolution in X-ALD dis-
ease [58]. However, Ito et al. [59] suggest the major mode of oli-
godendrocytic death in the brain of X-ALD patients is cytolysis,
rather than apoptosis.
In a model of Zellweger syndrome (Pex-13 null mice), neuronal
cell death and mitochondria-mediated oxidative stress have been
evidenced in cerebellum sections and in cultured cerebellarFig. 2. Incidence of peroxisomal dysfunction on physiopathological events involved in neu
somal dysfunctions can contribute to alteration of brain functions during aging and to the
dystrophies, Alzheimer’s disease). Peroxisomal dysfunctions converge on a condition of bio
turn, these events can contribute to amplify brain damages via secondary mitochondrial a
Galea et al. [48].neurons [54]. Both in primary neuronal cultures from the
neocortex and cerebellum of Pex11bþ/ and Pex11b/mice and in
the brain of these mice, neuronal cell death with typical charac-
teristics of apoptosis is observed: caspase-3 activation, membrane
leakage [53].
Several in vitro studies provided more information about the
processes involved in cell death induced by C22:0 and VLCFA
accumulation (C24:0, C26:0) on on mixed primary culture of glial
and neural cells [39]. This cell death is characterized by mito-
chondrial dysfunction and Ca2þ perturbation [39]. In murine 158N
oligodendrocyte cells treated with VLCFA (C24:0; C26:0), no sign of
apoptosis was observed [60] but mitochondrial depolarization
associated with an overproduction of superoxide anions and a loss
of lysosomal membrane integrity have been described [55]. Similar
results were observed on human neuronal cells SK-N-BE treated
with C22:0, C24:0 or C26:0 [61].
5. Potential role of peroxisomes in brain degeneration
5.1. Peroxisomes and aging
The implication of peroxisomes in cell aging and in the devel-
opment and progression of speciﬁc age-related degenerative
diseases is supported by the dysregulation of ROS and RNS- pro-
duction occurring in these organelles [62].
Human patients suffering from an inherited deﬁciency of
catalase (hypocatalasemia), face an increased risk of developing
age-related diseases including diabetes, atherosclerosis, and can-
cer [63]. Furthermore, cells from hypocatalasemic patients accu-
mulate hydrogen peroxide and harbor signs of age-associated
pathologies [64]. In hypocatalasemic conditions, the ability of
peroxisomes to import proteins, to regulate its growth and divi-
sion and to process ROS is altered [65]. Moreover, catalase is
suspected to play role in lifespan since longevity is positively
impacted by reduced cellular oxidative stress [62]. When cells
enter senescence (described as a loss of the ability of metabolically
active cells to replicate), catalase is translocated from the peroxi-
somes to the cytosol. Since restoration of catalase into the per-
oxisomes slows down senescence, catalase may represent arodegeneration. The schematic illustrates that common factors resulting from peroxi-
development of demyelinating and non-demyelinating diseases (peroxisomal leuko-
energetic failure, overproduction of ROS and activation of inﬂammatory processes. In
nd peroxisomal dysfunctions. This hypothesis is in agreement with that suggested by
D. Trompier et al. / Biochimie 98 (2014) 102e110108therapeutic target in the context of age-related diseases associated
with oxidative stress [62]. Interestingly, the efﬁciency of the
mitochondrial redox balance, a required condition to counteract
aging processes, is perturbed in catalase-deﬁcient cells and upon
generation of excess ROS inside peroxisomes [51]. In addition,
peroxisome life cycle may also be implicated in cellular aging.
After peroxisome division, heterogeneous population of peroxi-
somes is observed in cells. Young and vital nascent organelles are
present as well as old mature ones in which dysfunctional com-
ponents accumulate due to damages caused by products of
peroxisomal metabolism [66]. These old peroxisomes are elimi-
nated by autophagy to maintain organelle homeostasis and to
prevent accumulation of damaged peroxisomal compounds.
Noteworthy, the deletion of the protein ATG1, required for auto-
phagy, results in a signiﬁcant increase in peroxisome numbers,
accompanied with a decrease in cell viability in Hansenula poly-
morpha [67]. Moreover, in cells of advancing age, peroxisomal
import of PTS1 proteins is reduced [68]. Collectively, a wide
number of data support that peroxisomes are integrated into a
system that governs cellular aging, and that peroxisomal dys-
functions might favor the occurrence of age-related diseases.
5.2. Peroxisomes and Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia,
characterized by progressive neurodegeneration, particularly
affecting the hippocampal formation [69]. Impairment of cognitive
and memory functions associated with accumulation of intracel-
lular neuroﬁbrillary tangles (NFT), extracellular amyloid b (Ab)
peptide plaques and synaptic loss are the main important charac-
teristic of this disease [70]. Based on the decline of peroxisomal
activities with age [71], peroxisomal dysfunctions associated with
aging and dementia including decreased catalase activity [72],
lower plasmalogen synthesis [73], and increased sensitivity to cell
death, especially necrosis [74,75], might also favor neurodegener-
ative diseases such as AD [76,77].
The ﬁrst evidence of the potential role of peroxisomes in the
development of AD was established on primary rat hippocampal
neuron cultures. In these cells, peroxisomal proliferation, induced
by Wy-14.463, which is a potent peroxisome proliferator-activated
receptor a agonist, was shown to protect against cell death induced
by the Ab peptide [78]. Moreover, on the Tg2576 mouse model of
AD, signiﬁcant peroxisome alterations were observed in the
absence of apparent neuroanatomical or cytological signs of the
disease [79]. In a transgenic mouse model, harboring the human
Swedish familial AD mutation, the expression of ABCD3 and ACOX-
1 was found induced, possibly reﬂecting the need for efﬁcient fatty
acid b-oxidation, as a compensatory response to mitochondrial
dysfunctions [80]. In rat, impaired peroxisome activity triggered by
thioridazine also favors increased amyloid precursor protein (APP)
and b-secretase (BACE1) expression and Ab generation at least
partially by enhancing the VLCFA concentration [81].
In addition, substantial peroxisome-related alterations, which
may contribute to the progression of AD pathology, were reported
in humans. Several studies described a reduction of ethanolamine
plasmalogen and choline plasmalogen levels in brain regions and
erythrocyte of AD patients; this reduction was positively correlated
with disease severity [82,83]. Moreover, based on the neuropath-
ological Braak staging for AD, in stage VeVI patients, increased
levels of C22:0 and VLCFA (C24:0, C26:0), which are speciﬁc sub-
strates of peroxisomal b-oxidation, a decrease of plasmalogens, an
increased peroxisome volume density in neuronal cells and a
decreased peroxisome number in neurites in AD brain were re-
ported [84]. A reduction of DHA level was also observed in brain
and liver of AD patients [85].These results strengthen the hypothesis of the involvement of
peroxisomal dysfunctions in the physiopathology of AD. Altogether,
these data support a potential role of peroxisomes in neuro-
degeneration (Fig. 2).
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